Tesaro’s new ovarian drug will cost cancer patients $60,000 to $177,000 a year By: MarketWatch April 20, 2017 at 09:44 AM EDT The price is “a sticker shock” but will probably come closer to $119,000-a-year, one analyst said. Read More >> Related Stocks: Astrazeneca Plc ADR Clovis Oncology Inc Standard & Poors 500 Tesaro Inc